

Lucio C Rovati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4035610/publications.pdf>

Version: 2024-02-01

85
papers

4,779
citations

172386
29
h-index

95218
68
g-index

86
all docs

86
docs citations

86
times ranked

3531
citing authors

#	ARTICLE	IF	CITATIONS
1	I2-Imidazoline Ligand CR4056 Improves Memory, Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7320.	1.8	6
2	CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKC μ phosphorylation and membrane translocation in sensory neurons. <i>British Journal of Pharmacology</i> , 2020, 177, 48-64.	2.7	8
3	Improved efficacy, tolerance, safety, and abuse liability profile of the combination of CR4056 and morphine over morphine alone in rodent models. <i>British Journal of Pharmacology</i> , 2020, 177, 3291-3308.	2.7	5
4	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 9-19.	1.6	110
5	Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2564.	3.8	229
6	Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. <i>Arthritis Research and Therapy</i> , 2018, 20, 39.	1.6	26
7	Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis. <i>Journal of Pain Research</i> , 2017, Volume 10, 1033-1043.	0.8	16
8	Effect of selective CCK ₁ receptor antagonism on accommodation and tolerance of intestinal gas in functional gut disorders. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 288-293.	1.4	8
9	Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S34-S41.	1.6	35
10	The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S42-S48.	1.6	23
11	Correction: Wound healing properties of hyaluronan derivatives bearing ferulate residues. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7307-7307.	2.9	1
12	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	1.3	31
13	Wound healing properties of hyaluronan derivatives bearing ferulate residues. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7037-7045.	2.9	13
14	The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular). <i>Current Medicinal Chemistry</i> , 2015, 22, 2954-2971.	1.2	9
15	Efficacy of Andolast in Mild to Moderate Asthma: A Randomized, Controlled, Double-Blind Multicenter Study (The Andast Trial). <i>Current Pharmaceutical Design</i> , 2015, 21, 3835-3843.	0.9	13
16	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	1.6	29
17	Antiviral activity and safety profile of silybinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. <i>Transplant International</i> , 2014, 27, 696-704.	0.8	25
18	Development and validation of two liquid chromatography-tandem mass spectrometry methods for the determination of silibinin and silibinin hemisuccinate in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 945-946, 1-9.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 303-313.	1.6	239
20	Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. <i>Journal of Hepatology</i> , 2013, 58, 415-420.	1.8	49
21	Silibinin hemisuccinate binding to proteins in plasma and blood cell/plasma partitioning in mouse, rat, dog and man <i>in vitro</i> . <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 115-122.	0.3	3
22	Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 167-180.	1.2	51
23	A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1454-1460.	0.5	111
24	Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg. <i>Contraception</i> , 2012, 86, 359-365.	0.8	2
25	Crystalline Glucosamine Sulfate in the Treatment of Osteoarthritis: Evidence of Long-Term Cardiovascular Safety from Clinical Trials. <i>Open Rheumatology Journal</i> , 2011, 5, 69-77.	0.1	13
26	Identification and quantification of glucosamine in rabbit cartilage and correlation with plasma levels by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2011, 695, 77-83.	2.6	8
27	Experimental Pharmacology of Glucosamine Sulfate. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-8.	0.9	37
28	Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 819-827.	1.1	5
29	Conclusions not supported by methods and results. <i>BMJ: British Medical Journal</i> , 2010, 341, c6338-c6338.	2.4	13
30	Glucosamine Binding to Proteins in Plasma and Synovial Fluid and Blood Cell/Plasma Partitioning in Mouse and Man <i>In Vitro</i> . <i>Drug Metabolism and Drug Interactions</i> , 2009, 24, 211-27.	0.3	1
31	<i>In Vitro</i> Study of the Inhibition and Induction of Human Cytochromes P450 by Crystalline Glucosamine Sulfate. <i>Drug Metabolism and Drug Interactions</i> , 2009, 24, 195-209.	0.3	10
32	Bioequivalence Study of Generic Tablet Formulations Containing Ethinylestradiol and Chlormadinone Acetate in Healthy Female Volunteers. <i>Arzneimittelforschung</i> , 2009, 59, 651-658.	0.5	6
33	The reverse glucosamine sulfate pathway: application in knee osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 215-225.	0.9	8
34	Pharmacokinetic Profile of Dexloxiplumide. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1177-1188.	1.6	8
35	Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 844, 119-126.	1.2	56
36	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006, 54, 2339-2341.	6.7	5

#	ARTICLE	IF	CITATIONS
37	Use of crystalline glucosamine sulfate in osteoarthritis. <i>Future Rheumatology</i> , 2006, 1, 397-414.	0.2	3
38	Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 163-176.	1.1	6
39	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004, 11, 138-143.	0.8	104
40	Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. <i>Fertility and Sterility</i> , 2003, 80, 1495-1501.	0.5	71
41	Impact of the joint space width measurement method on the design of knee osteoarthritis studies. <i>Aging Clinical and Experimental Research</i> , 2003, 15, 136-141.	1.4	20
42	Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis. <i>Archives of Internal Medicine</i> , 2002, 162, 2113.	4.3	584
43	Influence of transdermal estradiol in the regulation of leptin levels of postmenopausal women: a double-blind, placebo-controlled study. <i>Menopause</i> , 2002, 9, 65-71.	0.8	10
44	Radiologic features poorly predict clinical outcomes in knee osteoarthritis. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 13-16.	0.6	72
45	Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2001, 357, 251-256.	6.3	1,116
46	Glucosamine sulphate and osteoarthritis. <i>Lancet, The</i> , 2001, 357, 1618.	6.3	3
47	Absorption, Distribution, Metabolism and Excretion of Glucosamine Sulfate. <i>Arzneimittelforschung</i> , 2001, 51, 699-725.	0.5	95
48	Monitoring bone effect of transdermal hormone replacement therapy by ultrasound investigation at the phalanx: a four-year follow-up study. <i>Menopause</i> , 2000, 7, 402-412.	0.8	36
49	CCKA Receptors in Gastrointestinal Disorders. , 2000, , 147-176.		1
50	Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R1718-R1724.	0.9	58
51	Glucosamine in osteoarthritis. <i>Lancet, The</i> , 1999, 354, 1640.	6.3	27
52	Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. <i>Osteoarthritis and Cartilage</i> , 1998, 6, 427-434.	0.6	217
53	Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders. <i>Expert Opinion on Investigational Drugs</i> , 1997, 6, 819-836.	1.9	18
54	Proglumide, a Cholecystokinin Receptor Antagonist, Reduces Neuroleptic Action in Huntingtonâ€™s Chorea. <i>European Neurology</i> , 1995, 35, 344-348.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. <i>Biological Psychiatry</i> , 1995, 37, 331-335.	0.7	31
56	Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. <i>Journal of Surgical Oncology</i> , 1994, 57, 11-16.	0.8	8
57	Loxiglumide inhibits cholecystokinin stimulated somatostatin secretion and simultaneously enhances gastric acid secretion in humans. <i>Regulatory Peptides</i> , 1994, 53, 185-193.	1.9	4
58	Effect of cholecystokinin-A-receptor blockade on oesophageal motility. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 983-990.	0.8	7
59	Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists. <i>Biorganic and Medicinal Chemistry Letters</i> , 1993, 3, 861-866.	1.0	2
60	Effect of loxiglumide on basal and gastrin and bombesin-stimulated gastric acid and serum gastrin levels. <i>Gastroenterology</i> , 1992, 103, 1215-1220.	0.6	23
61	Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. <i>Gastroenterology</i> , 1992, 102, 1654-1659.	0.6	69
62	Effects of Cholecystokinin Receptor Blockade on Circulating Concentrations of Glucose, Insulin, C-Peptide, and Pancreatic Polypeptide after Various Meals in Healthy Human Volunteers. <i>Pancreas</i> , 1992, 7, 1-10.	0.5	20
63	Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 3633-3640.	2.9	14
64	Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 28-38.	2.9	51
65	CR 2039, a new bis-(1H-tetrazol-5-yl) phenylbenzamide derivative with potential for the topical treatment of asthma. <i>European Journal of Pharmacology</i> , 1992, 229, 45-53.	1.7	9
66	Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. <i>European Journal of Pharmacology</i> , 1992, 216, 217-224.	1.7	23
67	Effect of loxiglumide and atropine on erythromycin-induced reduction in gallbladder volume in human subjects. <i>Hepatology</i> , 1992, 16, 937-942.	3.6	28
68	Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. <i>Gastroenterology</i> , 1991, 101, 503-511.	0.6	167
69	Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans. <i>Gastroenterology</i> , 1991, 100, 537-543.	0.6	147
70	Perspectives of CCK antagonists in pancreatic research and clinical use. <i>International Journal of Gastrointestinal Cancer</i> , 1991, 8, 215-226.	0.4	17
71	Cholecystokinin Receptor Antagonist Loxiglumide: Influence on Bilio-Pancreatic Secretion and Gastrointestinal Hormones in Man. <i>Digestion</i> , 1990, 46, 232-239.	1.2	11
72	Effect of Loxiglumide on Gallbladder Contractile Response to Cerulein and Food in Humans. <i>Gastroenterology</i> , 1990, 98, 1307-1310.	0.6	30

#	ARTICLE	IF	CITATIONS
73	Role of cholecystokinin in bombesin- and meal-stimulated pancreatic polypeptide secretion in dogs. <i>Digestive Diseases and Sciences</i> , 1990, 35, 1073-1077.	1.1	3
74	Benzodiazepines and their antagonists interfere with opioid-dependent stress-induced analgesia. <i>Pharmacology Biochemistry and Behavior</i> , 1990, 36, 123-126.	1.3	16
75	Comparison of the effect of lorglumide on pancreatic growth stimulated by camostate in rat and hamster. <i>Life Sciences</i> , 1990, 46, 281-286.	2.0	20
76	EFFECT OF A CHOLECYSTOKININ ANTAGONIST, LOXIGLUMIDE, ON PANCREATIC SECRETION IN PATIENTS WITH CHRONIC PANCREATITIS . <i>Biomedical Research</i> , 1990, 11, 151-156.	0.3	5
77	Proopiomelanocortin, Preproenkephalin-A and Preprocholecystokinin mRNA in the Hypothalamus of CCl4-Treated Rats. <i>Journal of Neuroendocrinology</i> , 1989, 1, 235-236.	1.2	0
78	Study into the role of cholecystokinin in bombesin-stimulated pancreatic growth in rats and hamsters. <i>European Journal of Pharmacology</i> , 1989, 161, 209-214.	1.7	22
79	Influence of Cholecystokinin Antagonist on the Effects of Cholecystokinin and Bombesin on Azaserine-Induced Lesions in Rat Pancreas. <i>Gastroenterology</i> , 1989, 96, 462-469.	0.6	88
80	Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion. <i>Gastroenterology</i> , 1989, 96, 1158-1164.	0.6	83
81	Effects of loxiglumide on gallbladder emptying in healthy volunteers. <i>Gastroenterology</i> , 1989, 97, 1331-1336.	0.6	73
82	Chronic intrathecal cannulation affects hypothalamic beta-endorphin and met-enkephalin concentrations. <i>Journal of Pharmacological Methods</i> , 1988, 19, 85-88.	0.7	4
83	Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. <i>Brain Research</i> , 1987, 410, 52-60.	1.1	59
84	The $\hat{1}^2$ -endorphin-induced secretion of growth hormone but not of prolactin is inhibited by an endogenous opioid antagonist. <i>European Journal of Pharmacology</i> , 1986, 129, 385-387.	1.7	7
85	Effects of Proglumide on Morphine Analgesia and Tolerance. <i>Annals of the New York Academy of Sciences</i> , 1985, 448, 630-632.	1.8	10